Jane Street’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.84M | Sell |
23,700
-3,400
| -13% | -$1.16M | ﹤0.01% | 2846 |
|
|
2025
Q4 | $10.8M | Sell |
27,100
-11,800
| -30% | -$5.22M | ﹤0.01% | 2241 |
|
|
2025
Q3 | $17.7M | Buy |
38,900
+14,900
| +62% | +$6.07M | ﹤0.01% | 1773 |
|
|
2025
Q2 | $7.83M | Sell |
24,000
-69,000
| -74% | -$19.1M | ﹤0.01% | 2448 |
|
|
2025
Q1 | $25.1M | Buy |
93,000
+45,800
| +97% | +$11.8M | 0.01% | 1125 |
|
|
2024
Q4 | $11.1M | Sell |
47,200
-41,300
| -47% | -$10.9M | ﹤0.01% | 1786 |
|
|
2024
Q3 | $24.3M | Sell |
88,500
-34,000
| -28% | -$8.85M | 0.01% | 1103 |
|
|
2024
Q2 | $29.8M | Sell |
122,500
-80,700
| -40% | -$12.7M | 0.01% | 989 |
|
|
2024
Q1 | $30.4M | Buy |
203,200
+105,300
| +108% | +$17.6M | 0.01% | 902 |
|
|
2023
Q4 | $18.7M | Sell |
97,900
-11,600
| -11% | -$1.98M | ﹤0.01% | 1323 |
|
|
2023
Q3 | $19.4M | Buy |
109,500
+72,500
| +196% | +$13.8M | 0.01% | 1123 |
|
|
2023
Q2 | $7.03M | Sell |
37,000
-16,900
| -31% | -$3.35M | ﹤0.01% | 2299 |
|
|
2023
Q1 | $10.8M | Sell |
53,900
-12,000
| -18% | -$2.52M | ﹤0.01% | 1565 |
|
|
2022
Q4 | $15.7M | Sell |
65,900
-34,400
| -34% | -$7.34M | 0.01% | 1196 |
|
|
2022
Q3 | $20.1M | Sell |
100,300
-171,300
| -63% | -$32.7M | 0.01% | 1065 |
|
|
2022
Q2 | $39.6M | Buy |
271,600
+88,600
| +48% | +$12.6M | 0.02% | 660 |
|
|
2022
Q1 | $29.9M | Sell |
183,000
-29,700
| -14% | -$4.52M | 0.01% | 976 |
|
|
2021
Q4 | $36.1M | Buy |
212,700
+47,600
| +29% | +$8.85M | 0.01% | 810 |
|
|
2021
Q3 | $31.2M | Buy |
165,100
+66,200
| +67% | +$12.4M | 0.01% | 827 |
|
|
2021
Q2 | $16.8M | Buy |
98,900
+87,700
| +783% | +$12.8M | 0.01% | 1224 |
|
|
2021
Q1 | $1.58M | Sell |
11,200
-30,700
| -73% | -$4.62M | ﹤0.01% | 4477 |
|
|
2020
Q4 | $5.45M | Sell |
41,900
-15,000
| -26% | -$2M | ﹤0.01% | 2030 |
|
|
2020
Q3 | $8.29M | Buy |
56,900
+49,000
| +620% | +$6.96M | 0.01% | 1367 |
|
|
2020
Q2 | $1.17M | Buy |
7,900
+1,600
| +25% | +$216K | ﹤0.01% | 3841 |
|
|
2020
Q1 | $686K | Buy |
6,300
+2,000
| +47% | +$231K | ﹤0.01% | 3279 |
|
|
2019
Q4 | $495K | Buy |
+4,300
| New | +$429K | ﹤0.01% | 3700 |
|
|
2019
Q3 | – | Sell |
-7,400
| Closed | -$537K | – | 5005 |
|
|
2019
Q2 | $537K | Buy |
+7,400
| New | +$568K | ﹤0.01% | 3491 |
|
|
2018
Q4 | – | Sell |
-10,700
| Closed | -$936K | – | 4870 |
|
|
2018
Q3 | $936K | Buy |
+10,700
| New | +$1.08M | ﹤0.01% | 2837 |
|
|
2018
Q2 | – | Sell |
-30,700
| Closed | -$3.66M | – | 4918 |
|
|
2018
Q1 | $3.66M | Buy |
30,700
+19,700
| +179% | +$2.54M | 0.01% | 1225 |
|
|
2017
Q4 | $1.4M | Sell |
11,000
-46,600
| -81% | -$5.86M | ﹤0.01% | 1945 |
|
|
2017
Q3 | $6.77M | Buy |
57,600
+52,000
| +929% | +$4.44M | 0.02% | 688 |
|
|
2017
Q2 | $447K | Buy |
+5,600
| New | +$358K | ﹤0.01% | 3168 |
|
|
2016
Q3 | – | Sell |
-5,000
| Closed | -$277K | – | 3952 |
|
|
2016
Q2 | $277K | Sell |
5,000
-14,600
| -74% | -$920K | ﹤0.01% | 3415 |
|
|
2016
Q1 | $1.23M | Buy |
19,600
+16,000
| +444% | +$1.06M | 0.01% | 1660 |
|
|
2015
Q4 | $339K | Buy |
+3,600
| New | +$334K | ﹤0.01% | 2942 |
|
|
2015
Q3 | – | Sell |
-14,700
| Closed | -$1.76M | – | 3522 |
|
|
2015
Q2 | $1.76M | Buy |
14,700
+10,300
| +234% | +$1.23M | 0.01% | 1089 |
|
|
2015
Q1 | $459K | Buy |
+4,400
| New | +$446K | ﹤0.01% | 2128 |
|
Other funds holding ALNY
VPM
VCM
Jane Street's ALNY Position: Q1 2026 in Review
Jane Street reduced its Alnylam Pharmaceuticals (ALNY) stake by 98% in Q1 2026, selling an estimated $104M and leaving 5,902 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #5136.
Jane Street first reported a position in ALNY in Q4 2013 and has held it in 43 quarters since. The position peaked at $437M in Q3 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Jane Street held 5,902 shares of Alnylam Pharmaceuticals worth $1.95M as of Q1 2026.
- Jane Street sold 305,386 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $104M.
- Alnylam Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5136 holding.
- Jane Street first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 43 quarters since.
- Jane Street's Alnylam Pharmaceuticals position peaked at $437M in Q3 2025.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.